Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1961
- Registration Number
- NCT03548935
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Taunton, United Kingdom
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 902
- Registration Number
- NCT03548987
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Odesa, Ukraine
A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 21
- Registration Number
- NCT03466567
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 462
- Registration Number
- NCT03457012
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Cambridge, Ontario, Canada
A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver
- Conditions
- Interventions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 67
- Registration Number
- NCT03357380
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 577
- Registration Number
- NCT03191396
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom
Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-05-08
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 58
- Registration Number
- NCT03144271
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 788
- Registration Number
- NCT03136484
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 302
- Registration Number
- NCT03086330
- Locations
- 🇷🇺
Novo Nordisk Investigational Site, St. Petersburg, Russian Federation
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 731
- Registration Number
- NCT03021187
- Locations
- 🇷🇺
Novo Nordisk Investigational Site, St. Petersburg, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.